Evaluating Chemotherapy Plus Adjuvant Radiation Therapy for Vulvar Cancer
Researchers found that adjuvant chemoradiation therapy was preferable over adjuvant radiation therapy alone for squamous cell carcinoma of the vulva.
SGO 2019
Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in BRCA-Mutant Ovarian Cancer
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
Pembrolizumab, Bevacizumab, Cyclophosphamide Combination for Ovarian Cancer: Promising Phase II Results
Tumor response rates were higher in patients with platinum-sensitive recurrent ovarian cancers, according to researchers
Social and Financial Assistance Programs to Overcome Barriers for Patients With Cervical Cancer
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
HPV Vaccination Influences Prevalence of Type-Specific HPV Infection
According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.
Racial Disparities in the Use of Brachytherapy to Treat Cervical Cancer
Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.
The Relationship Between Niraparib Dose Reduction and Efficacy in Ovarian Cancer
In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.
Simultaneous Sequencing of Paired Germline and Somatic Specimens Enhanced Clinical Care in Ovarian Cancer
Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.
Experience for Women With Ovarian Cancer After Multiple Lines of PARP Inhibitor Therapy
More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.
ARIEL3: Rucaparib Maintenance Across Age Groups in Advanced Ovarian Cancer
Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.
Next post in Gynecologic Cancer
